ArticleFrontiers in medicine2026
Thyroid autoantibodies predict long-term treatment response in euthyroid chronic spontaneous urticaria: a retrospective cohort study with propensity score matching.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic spontaneous urticaria (CSU) affects 0.5-1% of the population, with 40% remaining refractory to guideline-recommended therapy. Thyroid autoantibodies (TPOAb/TgAb) coexist in 20-30% of cases, yet their prognostic value in euthyroid patients remains controversial. Methods: We conducted a propensity score-matched retrospective cohort study of 350 euthyroid CSU patients between 2020 and 2023. The primary endpoint was Week 24 treatment response (complete/partial response defined by UAS7/UCT scores). Secondary outcomes included time-to-response, relapse rates, and treatment escalation requirements. Conditional logistic regression and Cox proportional hazards models assessed associations. Results: Antibody-positive patients exhibited significantly lower Week 24 response rates (47.6% vs. 69.4%; Conclusion: Thyroid autoantibody positivity independently predicts inferior long-term treatment response, delayed therapeutic onset, and increased relapse risk in euthyroid CSU patients. Routine TPOAb/TgAb screening at diagnosis could enable personalized treatment escalation, improving outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.